Safinamide mesylate

As a selective monoamine oxidase B (MAO-B) inhibitor, XADAGO offers a unique mechanism of action that complements traditional therapies, potentially improving motor function and reducing "off" time in patients. The increasing prevalence of Parkinson's disease and the growing demand for effective therapies create a substantial market opportunity for XADAGO, particularly in regions with aging populations. LAS VEGAS, April 22, 2025 /PRNewswire/ -- DelveInsight's " XADAGO/EQUFINA Market Size, Forecast, and Market Insight Report" highlights the details around XADAGO/EQUFINA, an inhibitor of monoamine oxidase B (MAO-B) indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of XADAGO/EQUFINA. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Newron Pharmaceuticals/Eisai/Meiji Seika Pharma's XADAGO/EQUFINA (safinamide) Overview XADAGO is a monoamine oxidase B (MAO-B) inhibitor used alongside levodopa/carbidopa to help manage "off" episodes in individuals with Parkinson's disease. While its exact mode of action in treating Parkinson's is not fully understood, it is thought to work by inhibiting MAO-B, thereby reducing dopamine breakdown. This leads to increased dopamine levels and enhanced dopaminergic activity in the brain. XADAGO contains the active ingredient safinamide in the form of a mesylate salt and is available in 50 mg and 100 mg film-coated oral tablets. Each tablet provides either 65.88 mg or 131.76 mg of safinamide mesylate, equivalent to 50 mg or 100 mg of the safinamide base. The medication is marketed as XADAGO in the United States and Europe and under the name EQUFINA in Japan. Learn more about XADAGO/EQUFINA projected market size for Parkinson's disease @ XADAGO/EQUFINA Market Potential Parkinson's disease is a progressive neurological disorder that mainly impairs movement control. It results from the slow degeneration of dopamine-producing neurons in the brain, especially in the substantia nigra, a region crucial for managing voluntary motor function. According to estimates by DelveInsight, there were 2.7 million diagnosed prevalent cases of Parkinson's disease in the 7MM in 2023, with the United States accounting for around 45% of these cases. While a cure for Parkinson's remains elusive, a combination of pharmacological and non-pharmacological therapies is used to manage symptoms. Physical, occupational, and speech therapies form key components of treatment, and surgical procedures may benefit select patients. Additionally, complementary therapies are sometimes employed to help address particular symptoms. Frequently prescribed medications for Parkinson's include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2A antagonists. These treatments primarily target motor symptoms, which are a major concern for those affected. DelveInsight reports that the Parkinson's disease market in the 7MM was valued at USD 3.2 billion in 2023. The market is expected to grow over the forecast period (2020–2034), fueled by the launch of new therapies, increasing prevalence, better access to healthcare, and rising demand for more advanced and effective treatment options. Discover more about the Parkinson's disease market in detail @ Parkinson's Disease Market Report Emerging Competitors of XADAGO/EQUFINA Some of the drugs in the pipeline include Solengepras (Cerevance), Minzasolmin (UCB Biopharma SRL/Novartis), Buntanetap (Annovis Bio), and others. Buntanetap has successfully completed Phase III trials for early-stage Parkinson's disease. Annovis Bio has scheduled a meeting with the FDA in Q1 2025 to determine the development path forward for Buntanetap in the treatment of Parkinson's disease. Buntanetap is also being developed for Alzheimer's disease, Lewy Body Dementia, and other neurodegenerative disorders. In November 2024, Cerevance announced the dosing of the first patient in its pivotal Phase III ARISE trial, evaluating solengepras as a potential adjunctive treatment for Parkinson's disease. Cerevance expects to report topline data in the first half of 2026. In December 2021, UCB partnered with Novartis to globally co-develop and co-commercialize UCB0599, a pioneering alpha-synuclein misfolding inhibitor currently in Phase II clinical trials for Parkinson's disease. To know more about the number of competing drugs in development, visit @ XADAGO/EQUFINA Market Positioning Compared to Other Drugs Key Milestones of XADAGO/EQUFINA In April 2020, Newron Pharmaceutical acknowledged that US WorldMeds, who held the US commercialization rights for the licensed drug, XADAGO, as a sub licensee of Zambon, had entered into a definitive agreement with Supernus Pharmaceuticals under which Supernus would acquire the CNS portfolio of US WorldMeds, including the US rights to XADAGO In November 2019, Eisai announced that it had launched the EQUFINA 50mg tablets for the indication of improvement of the wearing-off phenomenon in patients with Parkinson's disease under treatment with a drug containing levodopa in Japan. Manufacturing and marketing approval of EQUFINA was obtained in September 2019. In April 2017, Eisai Co., Ltd. and Meiji Seika Pharma announced entering into a license agreement for the commercialization of safinamide (development code: ME2125) to treat Parkinson's disease in Japan and Asia. In March 2017, Newron Pharmaceuticals announced the US FDA approval of XADAGO to treat Parkinson's disease as an add-on therapy to levodopa/carbidopa for patients experiencing "off" episodes. In March 2016, Zambon announced a strategic agreement with US WorldMeds to commercialize Newron's lead compound, XADAGO, to treat Parkinson's disease in the US. In February 2015, XADAGO was approved in the European Union as an add-on therapy to levodopa, alone or in combination with other Parkinson's medications, in mid-late stage PD patients with motor fluctuations. XADAGO/EQUFINA Patent Details XADAGO tablets are currently protected by three XADAGO patents with US patent numbers 8,076,515, 8,278,485, and 8,283,380, which expire between June 2027 and December 2028 and are listed in the FDA's publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. The company has a license agreement with Zambon S.p.A., Newron's partner, related to the XADAGO Patents, and as a new chemical entity, XADAGO is under the 5-year FDA exclusivity period that expires on March 21, 2022. In May 2017, Zambon filed a worldwide patent under the patent number WO2017207587A1. The invention relates to pharmaceutical compositions comprising safinamide and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles, and a process for preparing them. Discover how XADAGO/EQUFINA is shaping the Parkinson's disease treatment landscape @ XADAGO 50mg XADAGO/EQUFINA Market Dynamics XADAGO, marketed as EQUFINA in some regions (notably in South Korea and Japan), is a once-daily oral selective MAO-B inhibitor used as an add-on treatment for Parkinson's disease patients experiencing "off" episodes while on a stable dose of levodopa. The drug's unique dual mechanism of action—MAO-B inhibition and modulation of glutamate release—offers both dopaminergic and non-dopaminergic effects, positioning it as a differentiated product in the PD adjunctive therapy landscape. This has helped it carve a niche in markets where patients are inadequately controlled by levodopa alone, particularly those in mid-to-late-stage PD. The global market dynamics for XADAGO/EQUFINA are shaped by a mix of competitive intensity, regional adoption trends, and payer dynamics. In the U.S. and Europe, the drug has faced stiff competition from generic MAO-B inhibitors (like selegiline and rasagiline) and newer Parkinson's disease therapies, including COMT inhibitors, dopamine agonists, and extended-release levodopa formulations. Despite this, its favorable safety profile and once-daily dosing have supported its uptake in certain patient segments, especially in Europe. Market penetration has been slower in the U.S. due to both reimbursement hurdles and physician preference for more established adjunctive treatments. In Asia, particularly Japan and South Korea, EQUFINA has demonstrated stronger market performance thanks to focused commercial strategies and a high unmet need for effective "off time" management. Meiji Seika Pharma and Eisai, the regional marketing partners, have successfully leveraged the drug's differentiated profile in clinician education, which has led to growing adoption among neurologists. In Japan, where the aging population is rapidly expanding and Parkinson's prevalence is rising, EQUFINA has benefited from both demographic tailwinds and formulary access. Looking ahead, the market outlook for XADAGO/EQUFINA depends on several strategic levers, including lifecycle management, regional partnerships, and real-world evidence generation. The manufacturer's ability to expand into new geographies, secure favorable reimbursement, and differentiate against both generics and newer entrants will be critical. Moreover, as Parkinson's disease treatment moves toward more personalized approaches, XADAGO/EQUFINA may find sustained relevance in specific subpopulations, particularly those requiring a balance of efficacy and tolerability. Dive deeper to get more insight into XADAGO/EQUFINA's strengths & weaknesses relative to competitors @ XADAGO/EQUFINA Market Drug Report Table of Contents Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance, among others. Parkinson's Disease Pipeline Parkinson's Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others. Cell and Gene Therapy in Parkinson's Disease Market Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson's disease companies including MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics, among others. Parkinson's Disease Psychosis Market Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2024, and provided an outlook for 2025. Highlights 2024: Evenamide Exceptional data from study 014/015 and study 008A: Demonstrated significant and increasing efficacy of evenamide as an add-on therapy on multiple measures of psychopathology in treatment-resistant schizophrenia (TRS) and chronic schizophrenia Confirmed evenamide’s favorable safety and tolerability profile The data adds to the growing evidence that evenamide’s glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who are not benefiting from current antipsychotic treatments on the market Strategic licensing and partnerships: In December 2024, the Company announced a licensing agreement with EA Pharma, a subsidiary of Eisai, to develop, manufacture and commercialize evenamide in Japan and other designated Asian territories. Under the terms of the agreement, Newron will receive up to a maximum total of EUR 117 million, including an upfront payment of EUR 44 million, financial contributions to its upcoming pivotal Phase III one-year study of evenamide, milestone payments, and tiered royalties up to a double-digit percentage of net sales for evenamide Post-period, in January 2025, the Company announced a further licensing agreement with Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea. Under the terms of the agreement, Myung In Pharm will contribute 10% of the total patient population to be enrolled into Newron’s upcoming Phase III trial and cover the costs related to this population Upcoming milestones: Newron is planning to initiate a pivotal Phase III randomized, double-blind, one-year trial in Q2 2025 that will compare evenamide to placebo as an add-on treatment in patients with TRS The Company continues to pursue further development opportunities for evenamide in other territories Corporate Post-period, in March 2025, the Board of Directors of Newron proposed Dr. Chris Martin for election as Independent, Non-Executive Director and Chairman of the Board of Directors, at the Company’s upcoming Annual General Meeting, to be held on April 23, 2025. He is expected to succeed Dr. Ulrich Köstlin, who will end his twelve years of service on the Board of Newron following the completion of this year’s shareholder meeting Newron’s Board was strengthened in April 2024 through the appointment of Margarita Chavez as an Independent, Non-Executive Director and Chair of the Board’s Business Development Committee, bringing more than 20 years of US and international dealmaking expertise and leadership in the pharmaceutical industry In March 2024, the Company signed an agreement for the subscription of up to 2.05 million newly issued shares with an institutional investor focused on investing in high-growth firms across sectors including biotech and healthcare, with total proceeds generated of EUR 15 million Also in March 2024, an agreement with the European Investment Bank was reached to extend the near-term tranche repayment dates of its 2018 financing agreement until the end of 2025 and into 2026 Stefan Weber, CEO of Newron, commented: “The positive evenamide data and strong momentum from our partnering agreements have set the stage for our pivotal Phase III randomized, double-blind, one-year trial, that will compare evenamide to placebo as an add-on treatment in at least 600 patients with TRS. We expect to continue building on our progress in 2025 by initiating this clinical trial with the compound in Q2 2025, and pursuing further development opportunities for evenamide, in addition to the two licensing agreements announced to date. A key objective for 2025 will also be strengthening our institutional shareholder base, and the preparation of a potential registration of our shares in the USA, the key capital market for our industry. Newron’s total available cash resources, along with the proceeds deriving from the two licensing agreements for evenamide – signed with EA Pharma/Eisai Group in late December 2024 and with Myung In Pharm in early January 2025 – will fund the Company’s planned development programs and operations well through 2026.” “We encourage our shareholders to register for and participate in the upcoming Ordinary and Extraordinary shareholders’ meeting on April 23, 2025, as the proposed resolutions will materially contribute to the success of our ambitions. At these meetings, we will also bid a heartfelt farewell to Ulrich Köstlin and thank him for his many years of service as Newron's Chairman,” Stefan Weber added. Evenamide – advancing schizophrenia treatment 2024 was marked by significant milestones for the evenamide development program, with Newron reporting two sets of exceptional data on the use of evenamide as an add-on treatment for patients with TRS and chronic schizophrenia, as well as announcing its first licensing agreement: In January, the Company reported the final one-year results from study 014/015, a Phase II open label trial evaluating evenamide as an add-on therapy to a single antipsychotic in TRS patients. The data demonstrated that evenamide as an add-on treatment for patients with TRS was associated with sustained, clinically significant benefits that increased throughout the one-year course of treatment, with more than 70% of patients experiencing a clinically important reduction in disease severity. Remarkably, 25% of patients achieved “remission”, which represents the highest level of improvements that can be obtained in a patient with schizophrenia and has never been described before in TRS patients. Furthermore, approximately 50% of patients that completed one-year of treatment with evenamide no longer met the criteria used to diagnose treatment resistance; also, there were no patient relapses during the one-year treatment period. In April, Newron announced data from study 008A, a potentially pivotal four-week, randomized, double-blind and placebo-controlled Phase III study of evenamide as an add-on therapy in patients with chronic schizophrenia demonstrating inadequate benefit from their current second-generation antipsychotic. The study met its key safety and efficacy endpoints: the primary endpoint (improvement of the Positive and Negative Syndrome Scale PANSS Total Score) and key secondary endpoint (improvement of the Clinical Global Impression of Severity CGI-S), with a 96% rate of study completion. Additionally, no new or specific concerns were raised in the study. In May, further analysis of this data revealed significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings, confirming a highly statistically significant improvement for evenamide irrespective of the population analyzed or the statistical methods used. In addition, the benefits noted on efficacy measures continued to increase up to day 29, indicating potentially larger and more enduring effects following long-term treatment with evenamide. Together, the data from these studies reaffirmed evenamide’s favorable safety and tolerability profile and demonstrated its efficacy on multiple measures of psychopathology in TRS and chronic schizophrenia. The readouts also add to the growing evidence that the glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who do not benefit from current antipsychotic treatments. Financial key takeaways 2024: In 2024, Newron reported, for the first time since its inception, a net profit of EUR 15.8 million, compared with a net loss of EUR 16.2 million in 2023 License income in 2024 was EUR 44.5 million, predominantly resulting from the upfront payment due under the license agreement signed with EA Pharma/Eisai Group In addition, the Company received royalty payments for Xadago from Zambon of EUR 6.9 million (2023: EUR 6.7 million) Total revenues increased from EUR 9.1 million in 2023 to EUR 51.4 million in the reporting period Newron's R&D expenses increased to EUR 13.6 million (2024) from EUR 13.2 million in 2023 G&A expenses increased from EUR 7.5 million in 2023 to EUR 11.5 million in 2024, mostly due to one-time transaction-related costs As the upfront payment was transferred in January 2025, only, the cash used in operating activities increased to EUR 17.6 million in 2024, from EUR 10.1 million in 2023 Cash and other current financial assets as of December 31, 2024, were at EUR 9.8 million, compared to EUR 12.6 million at the beginning of the year. EUR 42 million of proceeds from the execution of the two licensing agreements with EA Pharma/Eisai Group and Myung In Pharm were collected net of withholding taxes, in January 2025. Financial Summary (IFRS) 2024 and 2023: In thousand EUR (except per share information) 2024 2023 License income from contracts with customers 44,470 58 Royalties from contracts with customers 6,920 6,735 Other income from contracts with customers 0 2,264 Revenue 51,390 9,057 Research and development expenses (13,642) (13,152) Operating Result 26,173 (11,629) Financial result, net (4,779) (4,571) Net gain/(loss) 15,843 (16,224) Gain/(Loss) per share 0.85 (0.91) Cash used in operating activities (17,614) (10,140) Cash, cash equivalents and Other current financial assets 9,826 12,599 Total assets 63,908 25,866 Newron’s Annual Report 2024 is available for download on the Company’s website at: www.newron.com/investors/reports-and-presentation/year/2024 Outlook 2025: Newron’s position has been strengthened in 2024 and early 2025 with licensing agreements and increased financial flexibility. Following a busy 2024 full of milestones for our evenamide development program, Newron expects to continue building on its progress in 2025 by initiating the pivotal Phase III clinical study of the compound in Q2 2025, and pursuing further development opportunities for evenamide in addition to the two licensing agreements announced to date. Newron is delighted with the progress of evenamide so far and is excited about the clear benefits that the development compound can bring to patients who are underserved by the antipsychotics currently on the market, and who are in great need of new and innovative treatments. The Company looks forward to providing an update on evenamide, including any business development opportunities, in due course. A key objective for 2025 will be strengthening the Company’s institutional shareholder base and the preparation of a potential registration of its shares in the USA, the key capital market for the Life Sciences industry. The Company’s total available cash resources together with the proceeds deriving from the signature of the two licensing agreements for evenamide with EA Pharma/Eisai Group in late December 2024 and with Myung In Pharm in early January 2025 are expected to fund Newron’s planned development programs and operations well through 2026. Media/analyst/investor Conference Call today at 3 pm CET/2 pm UK/9 am ET Newron’s management team will today present the 2024 full-year results and provide an update and guidance for 2025. Please dial in five to ten minutes prior to the beginning of the call using one of the following telephone numbers: Switzerland/Europe: +41 (0)58 310 50 00 United Kingdom: +44 (0)207 107 0613 United States: +1 (1)631 570 5613 For additional available numbers, please see here The presentation is available at www.newron.com/investors/reports-and-presentation/year/2024 2025 Shareholders’ Meeting Agenda: Newron’s Board of Directors has approved the below agenda for the April 23, 2025, Shareholders’ Ordinary and Extraordinary annual meeting, which will take place at the Company’s registered office (Via Antonio Meucci 3) in Bresso (Mi), Italy, starting at 10 am CET. The formal invitation to shareholders will be issued and disclosed in the statutory papers on or around April 1, 2025. All documents connected with the agendas as per applicable laws and regulations as well as the necessary information to register and attend these meetings will be made available on the Company’s website (www.newron.com/investors/shareholders-meeting) on the same day. The agenda is as follows: Ordinary part 1. Review and approval of the annual financial statements and presentation of the consolidated financial statements as of December 31, 2024. Connected and consequent resolutions; 2. Appointment of a new member of the Board of Directors, until the approval of the financial statements as of December 31st, 2025, as follows: 2.1 Proposal to appoint Chris Martin* in quality of new independent and non-executive director; 2.2 Proposal to appoint Chris Martin in quality of new non-executive Chairman of the Board; 2.3 Determination of the remuneration. Connected and consequent resolutions: 3. Appointment of the auditing company for the three fiscal-year term 2025-2027; connected and consequent resolutions; 4. Appointment of the statutory auditors for the three fiscal-year term 2025-2027 and determination of their fees. Connected and consequent resolutions; Extraordinary part 1. Proposal of attribution to the Board of Directors of powers, pursuant to art. 2443 of the Civil Code, to be executed during the next 5 years, to increase the share capital, in one or more times, for a maximum amount of nominal Euro 399,177.00, in addition to any premium, without option rights, pursuant to art. 2441, paragraph 4, second part of the Civil Code. Amendment of art. 6 of Newron By-law. Related and consequential resolutions; 2. Proposal of attribution to the Board of Directors of powers, pursuant to art. 2443 of the Civil Code, to be executed during the next 5 years, to increase the share capital, in one or more times, for a maximum amount of nominal Euro 119,753.00, in addition to any premium, with exclusion of the option rights, pursuant to art. 2441, paragraphs 5, 6 and/or 8 of the Civil Code, for one or more stock option plans. Amendment of art. 6 of Newron By-law. Related and consequential resolutions; 3. Proposal of attribution to the Board of Directors of powers, pursuant to art. 2443 and 2420-ter of the Civil Code, to be executed during the next 5 years, to increase the share capital, in one or more times, for a maximum amount of nominal Euro 1,397,120.00, in addition to any premium, by issuing shares and/or convertible bonds, with or without option rights, pursuant to art. 2441, paragraphs 4, first part, 5, 6 and/or 8 of the Civil Code, optionally cum warrant, optionally related to the listing of the shares or the other above mentioned instruments on NASDAQ and/or NYSE and/or on any other market. Amendment of art. 6 of Newron By-law. Related and consequential resolutions; 4. Creation of American Depositary Shares and listing them on the NASDAQ and/or NYSE and/or on any other market in the United States of America; connected and consequent resolutions * Dr. Chris Martin is a recognized leader in the biopharma industry who has taken therapeutic technology from the lab bench through to regulatory approval and global market sales. Over his career, he has raised more than $1.4 billion on the capital markets to support the development of his companies. He was instrumental in co-founding ADC Therapeutics in 2012 and served as its CEO from its inception until 2022. Under his tenure, the Swiss-based ADC Therapeutics grew from a private biotech start-up to a New York Stock Exchange listed leader in the field of antibody-drug conjugates (ADC) with products marketed worldwide. He co-founded and was the CEO of Spirogen Ltd, an innovator of ADC payload technology, which was subsequently sold to AstraZeneca for a total of up to $440 million. Currently chairing the boards of MyricxBio, Tagworks, Tokamak Energy Ltd. and serving on the boards of Osivax SAS, Solcom Ltd. and Senya therapeutics (all private companies), Chris Martin holds a bachelor’s degree in chemical engineering from Aston University, a DPhil in Engineering Science from the University of Oxford, and an MBA from IMD Business School. He is a British citizen and lives in Switzerland. Financial calendar AGM and EGM 2025: April 23, 2025 Half-year results and report 2025: September 16, 2025 About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson’s disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: www.newron.com Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.